Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758491 | 0.87 | KDM4C (0.49) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 | |
| SCHEMBL5756809 | 0.85 | CYP11B1 (0.48) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 | |
| SCHEMBL5756781 | 0.85 | CYP11B1 (0.48) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 | |
| SCHEMBL5759391 | 0.85 | CYP11B1 (0.48) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 | |
| SCHEMBL5758839 | 0.82 | HPGDS (0.59) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 | |
| SCHEMBL5757769 | 0.82 | KDM4C (0.49) | CYP11B1CYP11B2NPC1KDM4C | |
| SCHEMBL5756971 | 0.80 | CYP19A1 (0.47) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 | |
| SCHEMBL5757426 | 0.78 | HPGDS (0.48) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 | |
| SCHEMBL5754535 | 0.77 | CYP11B1 (0.47) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 | |
| SCHEMBL5758744 | 0.74 | KDM4A (0.55) | CYP11B1CYP11B2HPGDSCYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| US-6559172-B1 | Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics | SMITHKLINE BEECHAM CORPORATION | 2003-05-06 | — | — | US | claimed |
| JP-2003500357-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1194144-A4 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| EP-1194144-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000071120-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-30 | — | — | WO | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
| US-6673941-B2 | Disubstituted imidazoles useful in the treatment of bacterial infections | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-01-06 | — | — | US | disclosed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-6559172-B1 | Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics | SMITHKLINE BEECHAM CORPORATION | 2003-05-06 | — | — | US | disclosed |
| EP-1194144-A4 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1194144-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000071120-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | CYP11B1 831/4885CYP11B2 1175/4885HPGDS 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.